Rankings
▼
Calendar
PCRX Q4 2020 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena
PCRX
Pacira BioSciences, Inc.
$971M
Q4 2020 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$131M
+7.0% YoY
Gross Profit
$96M
73.1% margin
Operating Income
$19M
14.3% margin
Net Income
$15M
11.1% margin
EPS (Diluted)
$0.32
QoQ Revenue Growth
+11.5%
Cash Flow
Operating Cash Flow
$47M
Free Cash Flow
$32M
Stock-Based Comp.
$11M
Balance Sheet
Total Assets
$1.3B
Total Liabilities
$655M
Stockholders' Equity
$620M
Cash & Equivalents
$100M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$131M
$122M
+7.0%
Gross Profit
$96M
$91M
+5.7%
Operating Income
$19M
$2M
+995.8%
Net Income
$15M
-$5M
+397.0%
Revenue Segments
Product
$130M
99%
Royalty
$1M
1%
← FY 2020
All Quarters
Q1 2021 →